A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

NCT07215390 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

DRUG: APL-3007, pegcetacoplan (APL-2)
DRUG: APL-3007, pegcetacoplan (APL-2)
OTHER: Placebo, Syfovre

Sponsor

Apellis Pharmaceuticals, Inc.